Eli Lilly reported new Phase 3 results for orforglipron, its once-daily oral GLP-1 pill, showing patients with type 2 diabetes and obesity lost an average of 10.5% of body weight (22.9 lbs) at the highest dose, alongside a 1.8% reduction in A1C over 72 weeks. Cardiometabolic risk factors also improved, and the safety profile remained consistent with the GLP-1 class.
With these results from the ATTAIN-2 trial, Lilly now has the full clinical package needed for global regulatory submissions by year-end. Analysts highlight a potential manufacturing advantage for orforglipron, a small molecule that may scale more easily than peptide-based injectables.
Industry analysts see room for competition between Lilly and Novo Nordisk. Orforglipron may hold a manufacturing and cost advantage as a small molecule, while Novo’s oral semaglutide shows stronger weight-loss efficacy. The question remains whether patients and providers will favor the convenience of orforglipron’s anytime dosing or the stronger efficacy reported with semaglutide.
Sources
Eli Lilly
BioSpace
Fierce Biotech
Previous Orforglipron Coverage
Lilly’s Oral GLP-1 Falls Short of Expectations, Boosting Novo Nordisk
Lilly’s Oral GLP-1 Pill Shows Strong Phase 3 Results as Novo Submits Rival for FDA Approval
